Potential applications of lactic acid bacteria from Egyptian dairy products as novel antioxidant and anticancer agents.

IF 2.1 4区生物学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biotechnology Letters Pub Date : 2025-09-18 DOI:10.1007/s10529-025-03648-7

Reham A Madian, Amel A Ibrahim, Mohamed Yacout, Sameh Awad, Sarah A Aggag

{"title":"Potential applications of lactic acid bacteria from Egyptian dairy products as novel antioxidant and anticancer agents.","authors":"Reham A Madian, Amel A Ibrahim, Mohamed Yacout, Sameh Awad, Sarah A Aggag","doi":"10.1007/s10529-025-03648-7","DOIUrl":null,"url":null,"abstract":"Purpose: Several scientific studies have revealed the role of probiotic lactic acid bacteria and their metabolites, including antioxidant activity, which is required for reducing oxidative stress, and have implications for cancer treatment. This study evaluated the ability of isolates to exert antioxidative and in vitro anti-tumor effects against the HCT-116 colon cancer cell line, with fewer side effects compared to chemotherapy.Methods: The in vitro antioxidative capacity of LAB isolates was quantified against DPPH free radicals. The cytotoxicity effects against the HCT-116 cells were analyzed using the MTT assay, microscopic fluorescence, flow cytometry, and qRT-PCR analysis of immunomodulatory cytokines and cancer-related gene expression.Results: Seven LAB isolates exhibited potent antioxidant activity, scavenging 51.20 to 78.29% of DPPH free radicals. Lactobacillus delbrueckii subsp. bulgaricus (RE 254) demonstrated superior activity, with 78.29% scavenging and a ferric-reducing activity power of 38.04%. Conversely, Lactiplantibacillus plantarum (RE 298) showed 53.67% and 16.08% activity, respectively. At a concentration of 25 × 103 CFU/ml, both strains induced pronounced cytotoxic effects on HCT-116 cells after 72 h (71.1% for RE 254 and 62.5% for RE 298). This cytotoxicity was mediated by apoptosis, driven by the upregulation of IL-2 and the concomitant downregulation of key genes, including BCL-2, PARK, TARC, LIF, IL-4, IL-6, CD1A, and CD1B.Conclusion: The findings strongly suggest that RE 254 and RE 298 are compelling candidates for use as functional supplements and adjunctive therapeutics in colon cancer management. Their efficacy, demonstrated through multifaceted anti-tumor mechanisms, warrants further validation through in vivo studies to assess their clinical potential.","PeriodicalId":8929,"journal":{"name":"Biotechnology Letters","volume":"47 5","pages":"107"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Letters","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10529-025-03648-7","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Several scientific studies have revealed the role of probiotic lactic acid bacteria and their metabolites, including antioxidant activity, which is required for reducing oxidative stress, and have implications for cancer treatment. This study evaluated the ability of isolates to exert antioxidative and in vitro anti-tumor effects against the HCT-116 colon cancer cell line, with fewer side effects compared to chemotherapy.

Methods: The in vitro antioxidative capacity of LAB isolates was quantified against DPPH free radicals. The cytotoxicity effects against the HCT-116 cells were analyzed using the MTT assay, microscopic fluorescence, flow cytometry, and qRT-PCR analysis of immunomodulatory cytokines and cancer-related gene expression.

Results: Seven LAB isolates exhibited potent antioxidant activity, scavenging 51.20 to 78.29% of DPPH free radicals. Lactobacillus delbrueckii subsp. bulgaricus (RE 254) demonstrated superior activity, with 78.29% scavenging and a ferric-reducing activity power of 38.04%. Conversely, Lactiplantibacillus plantarum (RE 298) showed 53.67% and 16.08% activity, respectively. At a concentration of 25 × 10³ CFU/ml, both strains induced pronounced cytotoxic effects on HCT-116 cells after 72 h (71.1% for RE 254 and 62.5% for RE 298). This cytotoxicity was mediated by apoptosis, driven by the upregulation of IL-2 and the concomitant downregulation of key genes, including BCL-2, PARK, TARC, LIF, IL-4, IL-6, CD1A, and CD1B.

Conclusion: The findings strongly suggest that RE 254 and RE 298 are compelling candidates for use as functional supplements and adjunctive therapeutics in colon cancer management. Their efficacy, demonstrated through multifaceted anti-tumor mechanisms, warrants further validation through in vivo studies to assess their clinical potential.

查看原文本刊更多论文

埃及乳制品中乳酸菌作为新型抗氧化剂和抗癌剂的潜在应用。

目的：一些科学研究已经揭示了益生菌乳酸菌及其代谢产物的作用，包括抗氧化活性，这是减少氧化应激所必需的，并对癌症治疗有影响。本研究评估了分离物对HCT-116结肠癌细胞系发挥抗氧化和体外抗肿瘤作用的能力，与化疗相比，副作用更少。方法：测定乳酸菌对DPPH自由基的体外抗氧化能力。采用MTT法、显微荧光、流式细胞术、qRT-PCR分析免疫调节细胞因子和肿瘤相关基因表达，分析其对HCT-116细胞的细胞毒性作用。结果：7株乳酸菌具有较强的抗氧化活性，可清除51.20% ~ 78.29%的DPPH自由基。德尔布鲁氏乳杆菌亚种保加利亚菌（RE 254）的清除率为78.29%，还原铁的活性为38.04%。相反，植物乳杆菌（Lactiplantibacillus plantarum, re298）的活性分别为53.67%和16.08%。在浓度为25 × 103 CFU/ml的条件下，两株菌株对HCT-116细胞72 h后均有明显的细胞毒作用（RE 254为71.1%，RE 298为62.5%）。这种细胞毒性是由凋亡介导的，由IL-2的上调和伴随的关键基因（包括BCL-2、PARK、TARC、LIF、IL-4、IL-6、CD1A和CD1B）的下调驱动。结论：研究结果强烈表明，re254和re298是结肠癌治疗中功能性补充剂和辅助治疗的有力候选者。通过多方面的抗肿瘤机制证明了它们的有效性，值得通过体内研究进一步验证，以评估其临床潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology Letters 工程技术-生物工程与应用微生物

CiteScore

5.90

自引率

3.70%

发文量

108

审稿时长

1.2 months

期刊介绍： Biotechnology Letters is the world’s leading rapid-publication primary journal dedicated to biotechnology as a whole – that is to topics relating to actual or potential applications of biological reactions affected by microbial, plant or animal cells and biocatalysts derived from them. All relevant aspects of molecular biology, genetics and cell biochemistry, of process and reactor design, of pre- and post-treatment steps, and of manufacturing or service operations are therefore included. Contributions from industrial and academic laboratories are equally welcome. We also welcome contributions covering biotechnological aspects of regenerative medicine and biomaterials and also cancer biotechnology. Criteria for the acceptance of papers relate to our aim of publishing useful and informative results that will be of value to other workers in related fields. The emphasis is very much on novelty and immediacy in order to justify rapid publication of authors’ results. It should be noted, however, that we do not normally publish papers (but this is not absolute) that deal with unidentified consortia of microorganisms (e.g. as in activated sludge) as these results may not be easily reproducible in other laboratories. Papers describing the isolation and identification of microorganisms are not regarded as appropriate but such information can be appended as supporting information to a paper. Papers dealing with simple process development are usually considered to lack sufficient novelty or interest to warrant publication.